Diagnostic biomarkers for Alzheimer's disease: a regulatory view

Lancet Neurol. 2017 Aug;16(8):580-581. doi: 10.1016/S1474-4422(17)30223-5. Epub 2017 Jul 11.

Authors

M T Isaac¹, S Vamvakas², M B Isaac³

Affiliations

¹ Institute of Psychiatry, Neurology and Neuroscience, London, UK.
² European Medicines Agency, London E14 5EU, UK.
³ European Medicines Agency, London E14 5EU, UK. Electronic address: [email protected].

PMID: 28721916
DOI: 10.1016/S1474-4422(17)30223-5

No abstract available

Publication types

Comment

MeSH terms

Alzheimer Disease*
Amyloid beta-Peptides*
Biomarkers
Humans

Substances

Amyloid beta-Peptides
Biomarkers